{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009543","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.347634+00:00","generated_at":"2026-06-17T18:08:50.451951+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Ultragenyx board director Lars Ekman to retire after 2023 annual meeting","bullets":["Lars Ekman, M.D., Ph.D. will retire from the Board effective immediately after the 2023 Annual Meeting on June 7, 2023.","Retirement is for personal reasons and not related to any disagreement with the Company or management.","No replacement director has been announced as of the filing date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009543","json":"https://secwatch.observer/filing/0000950170-23-009543.json","markdown":"https://secwatch.observer/filing/0000950170-23-009543.md","text":"https://secwatch.observer/filing/0000950170-23-009543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/0000950170-23-009543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/rare-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:08:50.451951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0463f1c03","claim":"Lars Ekman retired as Director at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) of his decision to retire from the Board of Directors of the Company (the “ Board ”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023009543/0000950170-23-009543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}